Clinical Trial

Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to evaluate the safety and efficacy of CAR-ITNK cells therapy targeting CD70 and CLL1 in participants with relapsed/refractory Acute Myeloid Leukemia. Participants will receive a single infusion of CAR-ITNK cell therapy targeting CD70 and CLL1 and complete follow-ups over the next three years.
Trial Details
NCT Number NCT07336875
Lead Sponsor Tongji Hospital
Conditions R/R AML
Enrollment 30 participants
Start Date 2026-02-28
Primary Completion 2028-02-28 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-13